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Abstract: The precise mechanisms of pain perception and transmission in the central nervous system have not been fully 
elucidated. However, extensive data support a role for the monoamine neurotransmitters, serotonin and norepinephrine, in 
the modulation of pain. Experiments with animal models of pain indicate that noradrenergic interventions, and to a lesser 
extent serotonergic interventions, reduce pain-related behavior. This is supported by data from clinical trials in humans in 
which antidepressants have been shown to reduce pain and functional impairment in central and neuropathic pain condi-
tions.  These  effects  are  particularly  well-studied  in  trials  with  serotonin-norepinephrine  reuptake  inhibitors  (SNRIs), 
which have provided a useful tool in the clinician’s arsenal, particularly considering the limitations of other classes of pain 
medications such as opioids, anti-inflammatories, and anticonvulsants (i.e., limited efficacy, safety and tolerability issues). 
Moreover, painful physical symptoms are frequently comorbid with major psychiatric disorders such as major depressive 
disorder and anxiety disorders. This paper reviewed and summarized the rationale and potential role of SNRIs for the con-
trol of pain including clinical and preclinical background. Currently evidence does not definitely support a role of the 
SNRIs, while  limited data propose  a putative promise of SNRIs in the treatment of pain related disorders including  
fibromyalgia  and  depressed  patients  with  multiple  somatic  complaints.  More  researches  are  warranted  to  generalize  
currently available preliminary evidences.  
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INTRODUCTION 
  Although a number of neurotransmitters, neuromodula-
tors, and receptors are likely involved in modulating the as-
cending and descending pain pathways, serotonin and nore-
pinephrine  have  been  implicated  as  principal  mediators  of 
endogenous  analgesic  mechanisms  in  the  descending  pain 
pathways [22].  
  The precise mechanisms involved in the pathogenesis of 
persistent pain states are not fully understood, but there is 
growing recognition that the disinhibition and imbalance of 
serotonin and norepinephrine in endogenous pain inhibitory 
pathways may contribute to persistent pain [11]. It is known 
that  the  substances  which  have  the  most  prominent  anti-
nociceptive  effects  are  generally  inhibitory  neurotransmit-
ters, and their action is primarily mediated by the activation 
of descending inhibitory pathways which inhibit pain [18]. 
Descending input from the cortex, hypothalamus, and amy-
gdala  and  pretectal  nucleus  is  provided  to  the  midbrain 
periaqueductal gray, the rostroventral medulla, and the dor-
solateral pontomesencephalic tegmentum [22]. Both the ros-
troventral  medulla  and  dorsolateral  pontomesencephalic 
tegmentum project to the spinal dorsal horn. The descending 
pain pathways form an endogenous pain-modulating circuit  
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consisting  of  both  inhibitory  and  facilitatory  components  
[6, 18]. 
  There  have  been  numerous  studies  demonstrating  the 
analgesic  effect of antidepressants, providing growing  evi-
dence that antidepressants are beneficial in the treatment of 
so-called  'chronic  pain'  [30].  Data  is  strong  regarding  the 
pain-inhibiting effects of tricyclic antidepressants (TCA) and 
newer agents enhancing norepinephrine and serotonin neuro-
transmission.  In  contrast,  review  of  studies  with  selective 
serotonin  reuptake  inhibitors  (SSRIs)  revealed  inconsistent 
evidence of efficacy for migraine or tension headaches, dia-
betic neuropathy, and fibromyalgia, although several studies 
of  SSRI  treatment  for  mixed-chronic  pain  are  universally 
positive [19].  
  Among contemporary antidepressants, currently available 
preclinical and clinical data indicate that serotonin-norepine-
phrine reuptake inhibitors (SNRIs) may be the most promis-
ing agents for the modulation of pain symptoms. 
PRECLINICAL STUDIES 
  The CNS pathway responsible for inhibition of pain sen-
sation includes projections from various brainstem nuclei to 
the  spinal  cord  dorsal  horn  via  the  dorsolateral  funiculus 
(DLF). More specifically, DLF fibers are comprised of sero-
tonergic  projections  from  the  raphe  nuclei,  dopaminergic 
projections from the ventral tegmental area (VTA), and nora-
drenergic  projections  from  the  locus  coeruleus.  These  de-
scending fibers suppress pain transmission at the nociceptive  
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spinal cord neurons presumably by hyperpolarizing afferent 
sensory neurons using endogenous opioids, or serotonin and 
norepinephrine  as  principal  inhibitory  mediators.  [9].  The 
pain pathways are presented in Fig. (1). 
  Persistent pain results from changes in sensitivity within 
both ascending and descending pain pathways in the brain 
and the spinal cord [17]. Neuropathic pain (e.g. diabetic neu-
ropathy, postherpetic neuralgia) is a type of persistent pain 
that  arises  from  functional  changes  occurring  in  the  pain 
sensory  system  after  peripheral  nerve  injury.  Sustained  or 
prolonged  stimulation  of  sensory  afferents  due  to  tissue 
damage or peripheral nerve injury has been implicated in the 
initiation  and  maintenance  of  central  neuroplastic  changes 
culminating  in central neuronal hyperexcitability;  this  may 
be complicated by reduced inhibition of nociceptive neurons 
by neurotransmitters, such as serotonin and norepinephrine 
in both spinal and supraspinal structures [18].
  
  The  inhibitory  action  of  serotonin  on  structures  of  the 
dorsal  horn  may  be  mediated  by  activation  of  opioid-
releasing interneurons. In animal models, naloxone, an opioid 
antagonist, attenuates the analgesic effect of intraspinal sero-
tonin; similarly, serotonin antagonists interfere with analge-
sic  effects  of  morphine  infused  in  or  near  the  spinal  cord 
[25]. Studies have also shown that adrenergic receptors are 
pivotal in the control of pain management in animal models 
[15]. Subsequent formalin tests of rats treated with antide-
pressants and antagonists of monoamine receptors  indicate 
that adreno-and serotonin receptors are associated with anti-
nociception,  indicating  functional  interactions  between 
noradrenergic  and  serotonergic  neurons  as  mechanisms  of 
antidepressant-induced pain-control [43]. 
  A number of animal studies have suggested an important 
role of noradrenergic and serotonergic neurotransmitters in 
the processing of pain. Experimental studies have shown that 
serotonin  and  norepinephrine  agonists  given  intrathecally 
block pain-related behaviors [12,13], while other data sug-
gests that serotonin agonists such as fenfluramine elicit pain-
related behaviors by increasing neuronal release of substance 
P [14].  
  Additionally, serotonin receptor antagonists such as on-
dansetron given to rats intrathecally inhibited experimental 
pain  response  [15],  suggesting  that  excitatory  serotonergic 
descending pathways facilitate the expression of pain. It is 
likely that serotonin both inhibits and promotes pain percep-
tion  by  different  physiological  mechanisms,  in  contrast  to 
norepinephrine  which  is  predominately  inhibitory.  Addi-
tional evidence of the role of monoamines in pain modula-
tion comes from studies of antidepressant administration in 
animal  models  of  pain.  In  comparison  of  drugs  inhibiting 
serotonin or norepinephrine reuptake inhibition (desipramine, 
reboxetine,  fluoxetine  and  paroxetine),  the  norepinephrine 
reuptake  inhibiting  drugs  desipramine
  and  reboxetine  re-
versed tactile allodynia at an overall magnitude equivalent to 
that of the anticonvulsant gabapentin. However, discrepant 
effects were observed with the SSRIs paroxetine
 and fluoxet-
ine, indicating  a  more  important role of norepinephrine in 
pain inhibition compared to serotonin [23].  
  One experimental study found that microinjection of par-
oxetine into the basolateral amygdala or cingulate cortex in 
mice  reduced  anxiety-related  behavior,  and  microinjection 
into the primary somatosensory cortex significantly attenu-
ated thermal hyperalgesia [24]. However, these findings have 
not been consistently replicated in subsequent preclinical and 
clinical studies. Medications enhancing neurotransmission of 
both noradrenergic  and serotonergic pathways have shown 
antinociceptive properties in preclinical and clinical research. 
In particular, duloxetine, a potent SNRI significantly reduced 
pain  behavior  in  rats  during  paradigms  of  persistent  pain 
(formalin model) and neuropathic pain (L5/L6 spinal nerve 
ligation model), but not during a paradigm of acute nocicep-
tive  pain  (tail-flick  model)  [18].  This  effect  of  duloxetine 
was  more  potent  than  other  SNRIs  including  venlafaxine, 
milnacipran,  and  the  TCA  amitriptyline.  It  should  also  be 
noted that in this experiment low doses of the SSRI paroxet-
ine  or  the  norepinephrine  reuptake  inhibitor  (NRI)  thioni-
soxetine  alone  did  not  show  reduction  of  formalin  model 
persistent pain behavior, which was observed when medica-
tions were combined [3]; this further supports the importance 
of both serotonergic and noradrenergic mechanisms in pain 
 
 
 
 
 
 
 
 
Fig. (1). Circuit of pain modulatory pathway. Abbreviations: 5-HT, serotonin; NE, norepinephrine. Thick arrow indicates ascending pain 
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modulation and implies that medications affecting both neu-
rotransmitters have greatest effect. In addition, a number of 
studies have demonstrated the strong effect of milnacipran in 
the treatment of pain in rat models. In one such experiment, 
intrathecal administration of milnacipran but not paroxetine 
had  prominent  antiallodynic  effects  in  a  neuropathic  pain 
paradigm  [28].  Milnacipran  was  also  effective  in  acute 
treatment and prevention of repeated stress-induced hyperal-
gesia [37].  
  Morover, coadministration of milnacipran with tramadol 
potentiated  the  antihyperalgesic  effect  of  tramadol  in  rats, 
indicating  that  milnacipran  has  an  antihyperalgesic  effect 
mediated by opioidergic mechanisms as well as via seroton-
ergic and noradrenergic pathways [29].  
  In summary, preclinical data suggests that persistent and 
neuropathic pain may be inhibited by enhancement of nore-
pinephrine and serotonin transmission (both neurotransmit-
ters > norepinephrine alone > serotonin alone), and that defi-
ciencies  in  one  or  both  of  these  neurotransmitter  systems 
may contribute to hyperactive pain processing. 
AFFINITY TO MONOAMINE TRANSPORTERS AND 
MONOAMINE  REUPTAKE  INHIBITION  OF  CUR-
RENT SNRIS 
  TCAs such as imipramine and amitriptyline inhibit both 
serotonin and norepinephrine uptake in vitro to variable de-
grees,  indicating  their  potential  being  serotonin-norepine-
phrine  dual  uptake  inhibitors  [5].  However,  in  vivo  imi-
pramine and amitriptyline are rapidly metabolized to secon-
dary  amines  that  are  potent  and  selective  NRIs  for  which 
they substantially lose the practical effects of SNRIs [5]. In 
addition, TCAs are notorious their inherent side effects stem 
by  inhibition  of  multiple  receptors  such  as  muscarinic,  α-
adrenergic  and  histamine  H1  receptors.  Hence  relatively 
genuine SNRIs are venlafaxine, milnacipran and duloxetine 
in the current market. Given a pivotal role of serotonin and 
norepinephrine dual reuptake inhibition for pain control, the 
binding affinity of SNRIs  to serotonin  and norepinephrine 
transporter and reuptake inhibition effect in the synaptic cleft 
may be crucial in their clinical efficacy. However, differen-
tial effect of such medications on serotonin and norepineph-
rine neurotransmission has been suggested. A recent study 
has compared the ability between duloxetine and venlafaxine 
to block serotonin and norepinephrine transporters in vitro 
and in vivo [5]. Duloxetine potently inhibits binding to the 
human serotonin transporters and norepinephrine transporter 
approximately by 100 times and 300 times greater potency, 
respectively,  comparing  with  venlafaxine  [5].  In  addition, 
duloxetine inhibited serotonin and norepinephrine reuptake 
with Ki values of 4.6, 16 and 369 nM, respectively, while 
venlafaxine  inhibited  reuptake  with  17  and  34-fold  lower 
potency, respectively,  comparing with duloxetine [5]. This 
differential biding affinity and reuptake inhibition on mono-
amine transporters between duloxetine and venlafaxine are in 
support of a series of other studies [4, 20, 26, 33, 34]. This 
discrepancy has been also replicated in a recent study [38], 
although there has been some discrepancies in affinity results 
possible due to laboratory techniques and other factors. In 
the study, the affinity and selectivity of milnacipran, duloxet-
ine, and venlafaxine were compared for the human serotonin, 
norepinephrine,  and  dopamine  transporters  [38].  Study  re-
sults showed that milnacipran was the most norepinephrine 
selective compound in comparison with duloxetine and ven-
lafaxine [38]. Duloxetine was found to be the most potent of 
the agents tested in blocking the reuptake of serotonin. Ven-
lafaxine, in contrast, selectively bound to the serotonin trans-
porter,  but  not  the  norepinephrine  transporter  [38].  Mil-
nacipran  established  high  affinity  to  both  serotonin  and 
norepinephrine transporters as well as showing a strong abil-
ity of uptake inhibition at both serotonin and norepinephrine 
transporters [38]. The potency of affinity and reuptake inhi-
bition between three SNRIs for the transporters are presented 
in Table 1.  
  In this context, it is intriguing that the net effect of SNRIs 
results in increment of extracellular 5-HT and NE levels in 
prefrontal cortex, which is correlated with uptake blockade 
increasing extracellular levels of the neurotransmitters in the 
synapse [5]. A number of experimental studies on chronic 
pain have consistently shown its engagement with prefrontal 
cortex activity [41, 42]. Cognitive modulations of pain are 
related to activation of regions of interest in several prefron-
tal  brain  areas  (dorsolateral  prefrontal  cortex,  ventrolateral 
prefrontal  cortex  and  anterior  cingulated  cortex),  where 
eventually modulate the central and peripheral pain pathways 
in  some  crucial  regions  in  the  CNS  and  spinal  cord  (i.e., 
thalamus, periaqueductal gray and dorsal horn, see Fig. 1) 
[41, 42]. In fact the dorsolateral prefrontal cortex is directly 
and indirectly connected to the anterior cingulate cortex and 
thalamus,  and finally  to the periaqueductal gray,  a  critical 
part of the descending pain modulatory system [42]. In addi-
tion, the antidepressant effect has been shown to be involved 
with  activation  of  such  brain  areas  [10].  Hence  future  re-
searches should integrate in proper manner the findings of 
experimental model for binding affinity and uptake inhibi-
tion to monoamine transporter and the data of brain activa-
tions in functional imaging studies using with SNRIs in pa-
tients with pain.  
CLINICAL STUDIES 
  TCAs that inhibit the reuptake of norepinephrine or both 
norepinephrine and serotonin, such as amitriptyline and de-
sipramine,  have  demonstrated  efficacy  in  the  treatment  of 
chronic  pain  conditions  such  as  diabetic  neuropathy,  fi-
bromyalgia, chronic headaches, and post-herpetic neuralgia 
[30]. Their ability to relieve pain in these conditions appears 
to be independent of their antidepressant effect and may be 
directly related to their effect on neuronal reuptake of sero-
tonin and norepinephrine
 and in part by the increased dura-
tion or concentration of serotonin and norepinephrine in syn-
apses associated with central pain integration [25].  
  There has been extensive research to isolate the specific 
involvement of each neurotransmitter in the pain pathways. 
SNRIs have been shown to be more efficacious than mono-
amine  oxidase  inhibitors  in  producing  analgesia,  with  the 
analgesic effects of the antidepressants beginning before the 
antidepressant  effects.  It  is  known  that  antidepressants  are 
pharmacologically similar to opiates. The above observations 
combined,  indicate  that  serotonin  and  norepinephrine  do 
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  A  meta-analysis  of  39  placebo  controlled  studies  was 
done to estimate the effect of antidepressant-induced analge-
sia in chronic non-malignant pain. The average chronic pain 
patient  who  received  an  antidepressant  treatment  had  less 
pain than 74% of the chronic pain patients who received a 
placebo,  which  translates  to  a  statistically  significant  pain 
decrement and a statistically significant difference between 
drug and placebo [30]. A recent  meta-analysis of trials of 
antidepressants  in  the  treatment  of  fibromyalgia  indicates 
that TCAs have superior efficacy compared to placebo [27]. 
  Duloxetine has demonstrated efficacy in the treatment of 
fibromyalgia in two similarly designed pivotal randomized, 
double-blind, placebo-controlled clinical trials (RCTs) [1, 3], 
and it has become the first antidepressant medication to ob-
tain  US  FDA  approval  for  this  indication.  A  pooled  data 
analysis  from  these  two  RCTs  provides  greater  statistical 
power and more clearly illustrates the efficacy of duloxetine 
for  pain,  functional  impairment,  and  quality  of  life  in  fi-
bromyalgia  patients  [2].  The  pooled  data  set  included  pa-
tients treated with duloxetine 60 mg QD or 60 mg BID (n = 
326) vs. placebo (n = 212). Duloxetine demonstrated signifi-
cantly  greater  improvement  in  the  two  principal  efficacy 
measures of Brief Pain Inventory (BPI)-average pain severity 
score and the Fibromyalgia Impact Questionnaire (FIQ) total 
score as early as week 1 and continuing through the study 
endpoint (week 12). Duloxetine also established superiority 
to placebo on measures of quality of life and functional out-
come. The proven acute efficacy of duloxetine for fibromy-
algia was replicated in a 6-month RCT which also indicated 
the durability of treatment response [35]. Doses studies in-
cluded 60 mg/day and 120 mg/day, with the 60 mg/day dose 
showing better tolerability.  
  Another  SNRI  with  demonstrated  efficacy  in  the  treat-
ment of fibromyalgia is milnacipran, which is officially ap-
proved  for  the  treatment  of  major  depressive  disorder  in 
European and Asian countries, but not by the US FDA [31]. 
A New Drug Application (NDA) was submitted in Decem-
ber of 2007 to the US FDA for milnacipran in the treatment 
of  fibromyalgia,  which  includes  data  from  phase  III  trials 
involving more than 2,000 patients [31]. The potential effi-
cacy  of  milnacipran  in  the  treatment  of  fibromyalgia  has 
been reported in two published flexible dose, 12-week RCTs 
[13, 39], and three unpublished fixed dose, 15-week [7], 6-
month [8] and serial 1-year [14] RCTs. In such studies, mil-
nacipran  was  effective  in  pain  and  functional  domains  of 
fibromyalgia.  Currently  existing  acute  and  maintenance 
treatment data suggests that doses of 100 mg/d and 200 mg/d 
may be equally efficacioust, with better tolerability shown 
for the 100 mg/d dose of milnacipran. 
  A more limited body of data supports the efficacy of the 
SNRI venlafaxine in the treatment of fibromyalgia. A small 
short RCT (n=90) of venlafaxine 75 mg/d was inconclusive 
[45],  although  a  subsequent  extended  RCT  (n=15)  for  12 
weeks  showed  that  venlafaxine  treatment  was  associated 
with significant improvement in mean pain intensity and in 
disability compared to placebo; the small sample size limits 
definitive conclusions from this study [36].  
  Of note, all three of these SNRIs have demonstrated effi-
cacy in placebo-controlled studies in other pain syndromes, 
including neuropathic pain [32, 40, 44], headache [46], and 
multiple somatic pains [21]. 
ISSUES TO BE ADDRESSED IN THE FUTURE 
  There  have  been  no  direct  comparative  trials  between 
SNRIs and other antidepressants (e.g., SSRIs and TCAs) as 
well  as  other  agents  (e.g.,  gabapentin,  pregabalin,  sodium 
oxybate, and pramipexole) that showed potential effective-
ness for pain control. With these trials clinicians may have 
more valuable information about the differential role among 
each agent and hence a benefit/risk ratio could be taken into 
consideration on the choice of proper medication for indi-
vidual  patient.  Although  the  comparative  advantage  of  an 
SNRI compared to a TCA or a medication like gabapentin 
could  be  definitely  proved  by  a direct  comparison  trial,  it 
should be unlikely to be conducted due to several issues at 
this  point,  i.e.,  less  likelihood  of  financial  support  from 
pharmaceutical company, different doses between agents for 
pain control, comedications, multiple and complicated etio-
pathogenesis  of  pain  (i.e.,  combined  psychological  and 
physical factors).  
  Although  meta-analysis  only  reveals  indirect  compari-
sons about relative impact of independent variables, strength 
of relationship between variables and overall effectiveness of 
interventions among therapeutic agents and has publication 
bias, meta-analytic findings are consistently report the direct 
analgesic effects of antidepressants having a property of se-
rotonin and norepinephrine reuptake inhibition such as TCAs 
and  SNRIs  [12].  In  such  report,  antidepressants  including 
SNRIs were also found to improve health-related quality of 
life (standardized mean differences (SMD), -0.31; 95% CI, -
0.42 to -0.20) as well as proving analgesic effects (SMD, -
Table 1.  The Potency of Affinity (Ki, nmol/L) and Reuptake Inhibition Between Three SNRIs for the Transporters* 
  Transporter Binding  Reuptake Inhibition 
  Serotonin  Norepinephrine  Serotonin  Norepinephrine 
Duloxetine  0.07±0.01  1.17±0.11  3.7±1.1  20±6 
Milnacipran  8.44±1.57  22±2.58  151±24  68±10 
Venlafaxine  7.8±0.28  1,920±158  145±18  1,420±240 
*Results have discrepancy between studies and this table was only modified from one study since it has simultaneously compared the potency of affinity and uptake inhibition be-
tween duloxetine, milnacipran and venlafaxine [38]. SNRIs for Pain  Current Neuropharmacology, 2009, Vol. 7, No. 4    335 
0.43;  95%  confidence  interval  [CI],  -0.55  to  -0.30)[16]. 
Hence larger and more well-designed meta-analytic data may 
also provide useful information on this research field.  
  Clinical studies with different clinical domains, different 
age-gender  groups,  those  with  comorbidity  and  refractory 
cases will also provide further information about the role of 
SNRIs for such conditions. 
CONCLUSION 
  Copious  data  support  a  role  for  antidepressants  in  the 
treatment  of  chronic  pain  syndromes,  particularly  neuro-
pathic  pain  and  fibromyalgia.  The  mechanisms  underlying 
this role include inhibition of serotonin and norepinephrine 
reuptake leading to enhanced descending inhibition of cen-
trally  sensitized  pain.  Antidepressants  have  demonstrated 
analgesic effects in clinical studies in humans and in animal 
models of pain. This body of data suggests greater effects 
with dual-acting antidepressants enhancing serotonergic and 
noradrenergic transmission such as TCAs and SNRIs, with 
evidence also existing for a smaller effect from medications 
enhancing  norepinephrine  alone.  Data  supporting  pain-
reducing  effects  of  selectively  serotonergic  medications  is 
more limited, presumably due to the role of serotonin in both 
inhibiting and enhancing pain via descending pathways. As 
physiological  mechanisms  modulating  pain  expression  are 
further clarified, improved pharmacological interventions for 
central pain syndromes is expected. 
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